Published in Obesity and Diabetes Week, July 11th, 2005
The second-generation antisense drug did not cause any hypoglycemia (low blood sugar) and was well-tolerated. The data reported were from an interim analysis of a randomized, double-blind, placebo-controlled Phase 2 study in diabetic patients. Data were announced in an oral presentation by Lise Kjems, M.D., Ph.D., Executive Director, Metabolic Drug Development of Isis Pharmaceuticals, at the American Diabetes Association's (ADA) 65th Scientific Sessions in San Diego.
"The results we have reported for ISIS 113715 are encouraging. After just 6...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.